Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma: A Prospective, Multicenter, Open-label, Phase Ib/II Clinical Study
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 54
- 主要终点
- Dose-limiting toxicity (DLT) for Phase 1b
研究概览
简要总结
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of linperlisib combined with chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participate in the clinical study; fully understand and be informed about the study and sign the Informed Consent Form (ICF); willing to comply with and capable of completing all trial procedures;
- •Diagnosed with PTCL according to the 2022 revised WHO lymphoma classification standards based on pathological diagnosis by the research center
- •Using the Lugano 2014 lymphoma efficacy evaluation criteria, the patient must have at least one measurable or evaluable lesion
- •Treatment failure to at least one prior line of systemic standard therapy for PTCL.
- •Age ≥ 18 years
- •Expected survival greater than 12 weeks
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- •Adequate organ and bone marrow function
排除标准
- •Accompanied by hemophagocytic lymphohistiocytosis (HLH)
- •Lymphoma involvement in the central nervous system or meninges
- •Active infections
- •Uncontrolled clinical cardiac symptoms or diseases
- •Currently using (or unable to stop at least one week prior to the first dose) a known CYP3A strong inducer or strong inhibitor.
- •Currently using vitamin K antagonists, antiplatelet drugs, anticoagulants (or unable to stop them within one week prior to the start of the study treatment).
- •History of Human Immunodeficiency Virus (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS).
- •Patients with mental disorders or those unable to provide informed consent
研究组 & 干预措施
Linperlisib Combined with Chidamide
Patients will receive Chidamide 20 mg orally twice weekly (biw) in combination with Linperlisib at the RP2D (80 mg or 60 mg, po, qd). Each treatment cycle is 28 days.
干预措施: Linperlisib (Drug)
Linperlisib Combined with Chidamide
Patients will receive Chidamide 20 mg orally twice weekly (biw) in combination with Linperlisib at the RP2D (80 mg or 60 mg, po, qd). Each treatment cycle is 28 days.
干预措施: Chidamide (Drug)
结局指标
主要结局
Dose-limiting toxicity (DLT) for Phase 1b
时间窗: The first cycle (each cycle is 28 days) after administration
To identify the DLT
Overall response rate(ORR) for Phase 2
时间窗: Up to 24 months
The proportion of patients who achieve complete remission (CR) or partial remission (PR) as the best response.
次要结局
- Progression-free survival(PFS)(Up to 4 years)
- Complete response rate (CRR)(Up to 24 months)
- Duration of Response(DOR)(Up to 4 years)
- Overall survival(OS)(Up to 4 years)
研究者
Qingqing Cai
MD. PhD.
Sun Yat-sen University